GlassScriptPhysician profile
Laura D Flannery
NPI 1891058582
$44,477.76
in general payments reported to CMS, 2019-2025
29 companies · $12K in 2025
The $12K reported for 2025 was more than what 90% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $141 · 2020: $18K · 2021: $569 · 2022: $2,423 · 2023: $2,902 · 2024: $8,429 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $9,922 · Food and Beverage: $8,383 · Consulting Fee: $4,750 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $9,922.32 |
| Food and Beverage | $8,382.81 |
| Consulting Fee | $4,750.00 |
| Education | $116.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $14,014.71 | 2021-2025 | Corevalve Evolut R |
| Boston Scientific Corporation | $10,635.15 | 2019-2025 | Avvigo Guidance System, Opticross, General - Therapies |
| Medtronic Vascular, INC. | $10,500.00 | 2020 | |
| Abbott Laboratories | $4,115.26 | 2022-2025 | Navitor, Absolute Pro, Portico |
| Edwards Lifesciences Corporation | $2,764.18 | 2021-2025 | Evoque, Edwards Sapien 3 Ultra Transcatheter Heart Valve, Pascal |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $396.03 | 2021-2024 | Lifevest |
| Novo Nordisk INC | $298.83 | 2022-2025 | Wegovy, Ozempic |
| Janssen Pharmaceuticals, INC | $232.74 | 2021-2023 | Xarelto |
| Ge Healthcare | $173.71 | 2020 | |
| Amgen INC. | $155.30 | 2021-2024 | Repatha |
| Inari Medical, INC. | $121.61 | 2022 | |
| Jenavalve Technology, INC. | $112.15 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $112.10 | 2022 | |
| Merck Sharp & Dohme LLC | $92.19 | 2022-2023 | Verquvo |
| Heartflow, INC. | $85.89 | 2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $84.61 | 2021-2023 | Brilinta |
| Neurocrine Biosciences, INC. | $83.92 | 2023 | Ingrezza |
| Astellas Pharma US INC | $79.99 | 2021 | |
| Novartis Pharmaceuticals Corporation | $74.78 | 2021-2022 | |
| Zoll Circulation INC | $68.00 | 2022 | |
| Stryker Corporation | $53.53 | 2025 | Flowtriever, Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| E.R. Squibb & Sons, L.L.C. | $46.13 | 2021-2023 | Camzyos |
| Pfizer INC. | $42.57 | 2023-2024 | |
| Philips North America LLC | $38.66 | 2019-2021 | |
| Getinge USA Sales, LLC | $22.88 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.23 | 2022 | |
| Biotronik INC. | $17.97 | 2022 | |
| Shockwave Medical, INC | $17.25 | 2025 | |
| Teleflex LLC | $16.39 | 2024 | Turnpike |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Flannery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.